Sequana Medical NV (BR:SEQUA) — Market Cap & Net Worth
Market Cap & Net Worth: Sequana Medical NV (SEQUA)
Sequana Medical NV (BR:SEQUA) has a market capitalization of $47.76 Million (€40.85 Million) as of August 4, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #22022 globally and #92 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sequana Medical NV's stock price €0.61 by its total outstanding shares 78172033 (78.17 Million). Review total liabilities of Sequana Medical NV to assess the company's total debt and financial obligations.
Sequana Medical NV Market Cap History: 2019 to 2026
Sequana Medical NV's market capitalization history from 2019 to 2026. Data shows change from $572.11 Million to $55.84 Million (-27.10% CAGR).
Index Memberships
Sequana Medical NV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL Small
BELS
|
$5.84 Billion | 0.82% | #20 of 20 |
|
BEL All Share
BSPT
|
$853.51 Billion | 0.01% | #94 of 108 |
Weight: Sequana Medical NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sequana Medical NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sequana Medical NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2638.28x
Sequana Medical NV's market cap is 2638.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $572.11 Million | $970.64K | -$14.98 Million | 589.42x | N/A |
| 2020 | $1.08 Billion | $963.28K | -$19.11 Million | 1119.53x | N/A |
| 2021 | $690.92 Million | $370.50K | -$23.62 Million | 1864.83x | N/A |
| 2022 | $548.35 Million | $922.69K | -$30.76 Million | 594.29x | N/A |
| 2023 | $365.57 Million | $712.17K | -$32.56 Million | 513.31x | N/A |
| 2024 | $279.66 Million | $106.00K | -$44.65 Million | 2638.28x | N/A |
Competitor Companies of SEQUA by Market Capitalization
Companies near Sequana Medical NV in the global market cap rankings as of August 4, 2026.
Key companies related to Sequana Medical NV by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #113 globally with a market cap of $186.27 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #180 globally with a market cap of $130.57 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #239 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #113 | Abbott Laboratories | NYSE:ABT | $186.27 Billion | $107.12 |
| #180 | Stryker Corporation | NYSE:SYK | $130.57 Billion | $341.20 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #239 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $86.68 |
Sequana Medical NV Historical Marketcap From 2019 to 2026
Between 2019 and today, Sequana Medical NV's market cap moved from $572.11 Million to $ 55.84 Million, with a yearly change of -27.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €55.84 Million | -3.63% |
| 2025 | €57.94 Million | -79.28% |
| 2024 | €279.66 Million | -23.50% |
| 2023 | €365.57 Million | -33.33% |
| 2022 | €548.35 Million | -20.63% |
| 2021 | €690.92 Million | -35.93% |
| 2020 | €1.08 Billion | +88.50% |
| 2019 | €572.11 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Sequana Medical NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.76 Million USD |
| MoneyControl | $47.76 Million USD |
| MarketWatch | $47.76 Million USD |
| marketcap.company | $47.76 Million USD |
| Reuters | $47.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sequana Medical NV
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid over… Read more